Prevention of different hydration options on cisplatin induced nephrotoxicity: a systematic review and meta analysis

Yu Wu¹, Yue Zhu¹, Wanfen Zhang¹, Cheng Chen¹, and Tongqiang Liu¹

Affiliation not available


August 17, 2020


Abstract

Purpose:Cisplatin-induced nephrotoxicity (CIN) is still the most serious side effect limiting the use of cisplatin. It affects up to 20% of patients. So, there are many precautions to avoid it. The purpose of this study was to conduct a systematic review and meta-analysis to evaluate and determine different hydration options that could provide protection against cisplatin-induced nephrotoxicity. Methods:A computerized literature search of PubMed, Embase, and Cochrane databases was performed. Trials were eligible if they enrolled patients receiving cisplatin and participants to receive different hydration options to prevent nephrotoxicity. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for combinations of studies. Results:Within 1111 eligible studies, 31 articles fulfilling the selection criteria were included in the review. A meta-analysis could only be performed on the 9 retrospective studies concerning magnesium supplementation, and showed nephroprotective effect of CIN (OR0.21, [0.59–0.29]). Conclusion:Although up to now, there is no one method of prevention that shows its indisputable efficacy, our results highlight the potential protective effect of magnesium supplementation on CIN.

Hosted file

a system review and meta ananlysis.doc available at https://authorea.com/users/351458/articles/476072-prevention-of-different-hydration-options-on-cisplatin-induced-nephrotoxicity-a-systematic-review-and-meta-analysis





	Mg group		Non-Mg group			Odds Ratio		Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	Year		M-H, Fixe	ed, 95% CI	
Kidera 2014	4	67	123	334	19.8%	0.11 [0.04, 0.31]	2014		_		
Oka 2014	1	44	9	41	4.7%	0.08 [0.01, 0.69]	2014				
Yoshida 2014	23	161	133	335	37.9%	0.25 [0.15, 0.41]	2014		-		
Yamamoto 2015	1	14	10	14	4.7%	0.03 [0.00, 0.32]	2015	_			
Yamamoto 2016	11	37	25	37	9.0%	0.20 [0.08, 0.54]	2016				
Yamaguchi 2017	9	60	20	62	8.6%	0.37 [0.15, 0.90]	2017		_		
Saito 2017	20	29	27	29	4.3%	0.16 [0.03, 0.85]	2017				
Kimura 2018	3	56	24	65	10.8%	0.10 [0.03, 0.34]	2018				
Ashraf 2019	4	22	1	24	0.4%	5.11 [0.52, 49.79]	2019		_	-	
Total (95% CI)		490		941	100.0%	0.21 [0.15, 0.29]			•		
Total events	76		372								
Heterogeneity: Chi ² =	16.08, df =	8 (P =	0.04); I ² =	50%				-		1 10	4000
Test for overall effect:	Z = 9.49 (F	P < 0.0	0001)					0.001	0.1 Favours [Mg group]	1 10 Favours [Non-M	1000 g group]

	up	Non-Mg	group		Odds Ratio		Odds Ratio			
		Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixed, 95% CI		
3.1.1 cisplatin < 80mg/i		14	10	14	4.7%	0.03 [0.00, 0.32]				
Yamamoto 2016	11	37	25	37	9.0%	0.20 [0.08, 0.54]				
Saito 2017 Subtotal (95% CI)	20	29 80	27	29 80	4.3% 18.0%	0.16 [0.03, 0.85] 0.15 [0.07, 0.32]	2017	•		
Total events	32		62							
Heterogeneity: Chi2 = 2.	14, df = 2	2(P = 0)	0.34); I ² = 7	7%						
Test for overall effect: Z	= 4.82 (F	< 0.0	0001)							
3.1.2 80mg/m ² <cispla< td=""><td>tin< 100</td><td>0ma/m</td><td>2</td><td></td><td></td><td></td><td></td><td></td></cispla<>	tin< 100	0ma/m	2							
Yoshida 2014	23	161	133	335	37.9%	0.25 [0.15, 0.41]	2014			
Oka 2014	1	44	9	41	4.7%	0.08 [0.01, 0.69]	2014			
Yamaguchi 2017	9	60	20	62	8.6%	0.37 [0.15, 0.90]	2017			
Kimura 2018	3	56	24	65	10.8%	0.10 [0.03, 0.34]	2018			
Subtotal (95% CI)		321		503	61.8%	0.23 [0.15, 0.34]		◆		
Total events	36		186							
Heterogeneity: Chi ² = 3.	96, df = 3	3 (P = 0	0.27); I ² = 2	24%						
Test for overall effect: Z	= 7.31 (F	< 0.0	0001)							
3.1.3 cisplatin≫100mg	/m ²									
Kidera 2014	4	67	123	334	19.8%	0.11 [0.04, 0.31]	2014			
Ashraf 2019	4	22	1	24	0.4%	5.11 [0.52, 49.79]	2019			
Subtotal (95% CI)		89		358	20.2%	0.21 [0.10, 0.45]		•		
Total events	8		124							
Heterogeneity: Chi2 = 9.	10, df = 1	I (P = (0.003); I ² =	89%						
Test for overall effect: Z	= 3.97 (F	< 0.0	001)							
Total (95% CI)		490		941	100.0%	0.21 [0.15, 0.29]		◆		
Total events	76		372							
Heterogeneity: Chi ² = 16	6.08. df =	8 (P =	0.04); I ² =	50%						
Test for overall effect: Z								0.01 0.1 1 10 10		
Test for subgroup differe				P = 0.62) I ² = 0%			Favours [Mg group] Favours [Non-Mg group]		

Hosted file

Table .docx available at https://authorea.com/users/351458/articles/476072-prevention-of-

 ${\tt different-hydration-options-on-cisplatin-induced-nephrotoxicity-a-systematic-review-and-meta-analysis}$